(Q30355133)

English

Active metabolite from Tamiflu solution is bioequivalent to that from capsule delivery in healthy volunteers: a cross-over, randomised, open-label study.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

Active metabolite from Tamiflu solution is bioequivalent to that from capsule delivery in healthy volunteers: a cross-over, randomised, open-label study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

1 reference

based on heuristic

inferred from title

author name string

Brewster M

1

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

Smith JR

2

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

Dutkowski R

3

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

Robson R

4

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

language of work or name

0 references

publication date

9 June 2006

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

44-46

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

6660-6663

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

Impact of epidemic type A influenza in a defined adult population

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.080

7 January 2021

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.080

7 January 2021

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.080

7 January 2021

Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.080

7 January 2021

Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.080

7 January 2021

Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.080

7 January 2021

Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.080

7 January 2021

H5N1 influenza and the implications for Europe

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.080

7 January 2021

Confronting the avian influenza threat: vaccine development for a potential pandemic.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.080

7 January 2021

Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.080

7 January 2021

Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.080

7 January 2021

The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.080

7 January 2021

Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.080

7 January 2021

Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.080

7 January 2021

The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.080

7 January 2021

Early administration of oral oseltamivir increases the benefits of influenza treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.080

7 January 2021

Pandemic influenza: is an antiviral response realistic?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.080

7 January 2021

Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.080

7 January 2021

Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.080

7 January 2021

Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.05.080

7 January 2021

Identifiers

10.1016/J.VACCINE.2006.05.080

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30355133&oldid=1550184253"